Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PTC THERAPEUTICS, INC. Director's Dealing 2015

May 12, 2015

31046_dirs_2015-05-11_fb8dcaf6-c72c-46a1-8e58-2d05999669c8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2015-05-07

Reporting Person: SCHMERTZLER MICHAEL (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-05-07 Common Stock J 1125722 Disposed 4569 Indirect
2015-05-11 Common Stock J 848 Disposed 3721 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 26766 Direct
Common Stock 1320369 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $51 2025-01-01 Common Stock (24000) 24000 Direct
Stock Option (Right to Buy) $27.05 2024-01-27 Common Stock (20000) 20000 Direct
Stock Option (Right to Buy) $10.85 2023-05-15 Common Stock (60000) 60000 Direct
Stock Option (Right to Buy) $218.4 2022-01-10 Common Stock (276) 276 Direct
Stock Option (Right to Buy) $490.8 2021-04-27 Common Stock (276) 276 Direct
Stock Option (Right to Buy) $1149.6 2020-02-02 Common Stock (216) 216 Direct
Stock Option (Right to Buy) $508.8 2019-10-07 Common Stock (266) 266 Direct
Stock Option (Right to Buy) $735.6 2018-01-25 Common Stock (166) 166 Direct
Stock Option (Right to Buy) $735.6 2018-07-14 Common Stock (83) 83 Direct
Stock Option (Right to Buy) $626.4 2017-04-18 Common Stock (125) 125 Direct
Stock Option (Right to Buy) $392.4 2016-03-01 Common Stock (90) 90 Direct

Footnotes

F1: Represents 26,766 shares of common stock of the Issuer ("common stock") directly held by the reporting person.

F2: Represents final distributions in kind, without consideration to the applicable limited partners, of common stock of the Issuer effected by Credit Suisse First Boston Equity Partners (Bermuda), L.P. (879,798 shares) and Credit Suisse First Boston Equity Partners, L.P. (245,924 shares). The shares of common stock distributed were initially received by these funds upon the automatic conversion of preferred stock at the time of the Issuer's initial public offering in June 2013. The reporting person is a managing director of Aries Advisors, LLC, the sub-advisor to Credit Suisse First Boston Equity Partners, L.P. The reporting person disclaims beneficial ownership of the distributed shares of common stock except to the extent of his pecuniary interest therein.

F3: Consists of (i) 3,487 shares of common stock held by EMA Private Equity Fund 1999 LP; (ii) 848 shares of common stock held by Credit Suisse First Boston U S Executive Advisors LP; and (iii) 234 shares of common stock held by Credit Suisse First Boston Finders and Screeners LP. The reporting person disclaims beneficial ownership of the shares of common stock held by these entities.

F4: Represents dispositions pursuant to Rule 144 of 848 shares of common stock at a weighted average price of $55.6807 per share by Credit Suisse First Boston U S Executive Advisors LP. Although included in the reporting person's prior ownership reports, the reporting person disclaims beneficial ownership of the disposed securities.

F5: Consists of (i) 3,487 shares of common stock held by EMA Private Equity Fund 1999 LP; and (ii) 234 shares of common stock held by Credit Suisse First Boston Finders and Screeners LP. The reporting person disclaims beneficial ownership of the shares of common stock held by these entities.

F6: Represents shares of common stock held by Section Six Partners, L.P. The reporting person is a general and limited partner of, and trustee of certain family trusts holding interests in, Section Six Partners, L.P. The reporting person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein.

F7: This option was granted on May 15, 2013 and vests over three years, with 8.33% of the shares underlying the option vested on August 15, 2013 and an additional 8.33% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter.

F8: Currently exercisable.